Get the Stockscreener App
15.15
1.43%
-0.22
Q 32 Bio Inc stock is traded at $15.15, with a volume of 311.85K.
It is down -1.43% in the last 24 hours and down -17.93% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$15.37
Open:
$15.45
24h Volume:
311.85K
Relative Volume:
0.22
Market Cap:
$451.01M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
5.6886
EPS:
2.6632
Net Cash Flow:
$-27.40M
1W Performance:
-2.88%
1M Performance:
-17.93%
6M Performance:
+288.46%
1Y Performance:
+705.85%
1-Day Range:
$14.93
$15.47
1-Week Range:
$14.79
$16.69
52-Week Range:
$1.62
$23.57
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
15.15 | 457.56M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB - MarketBeat
Q32 Bio Inc (NASDAQ: QTTB) Stock Price, News & Analysis - Kalkine
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB) - MarketBeat
Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Q32 Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Q32 Bio tops estimates as alopecia drug advances toward late-stage trials (QTTB:NASDAQ) - Seeking Alpha
Q32 Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Q32 Bio Inc. posts second quarter 2026 results and updates corporate outlook - Traders Union
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) adds $187.6M follow-on cash for AA drug - Stock Titan
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio Inc. Revenue Breakdown – NASDAQ:QTTB - TradingView
Q32 Bio Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Q32 Bio Inc (QTTB) Institutional Confidence - tradingkey.com
Q32 Bio Inc. SEC Filing (Jul 29, 2026) - Stock Titan
H.C. Wainwright raises Q32 Bio stock price target to $36 on alopecia drug outlook - Investing.com
Q32 Bio Inc. Files Registration for 6.875 Million Shares Resale by Private Placement Investors - Kalkine Media
Q32 Bio Inc (QTTB) Balance Sheet - TradingKey
Q32 Bio Inc (QTTB) Income Statement - TradingKey
Q32 Bio Inc (QTTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q32 Bio Inc (QTTB) Cash Flow - TradingKey
QTTB|Q32 Bio Inc|Price:15.060|Chg%:-0.150 - TradingKey
QTTB|Q32 Bio Inc|Price:15.140|Chg%:-0.010 - TradingKey
Q32 Bio Inc (QTTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Q32 Bio Inc (QTTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Q32 Bio Inc (QTTB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q32 Bio Inc Revenue Breakdown – DUS:DB0 - TradingView
Q32 Bio (QTTB) awards 10,826 stock options to director - Stock Titan
Q32 Bio (QTTB) corrects director’s 10,826 stock option award in Form 4/A - Stock Titan
Stock option grant for Q32 Bio Inc. (QTTB) director corrects prior award - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Q32 Bio Inc For: 21 July By Investing.com - Investing.com Canada
Form 13D/A Q32 Bio Inc. For: 21 July By Investing.com - Investing.com Canada
Q32 Bio Inc. (QTTB) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Management in Pre-Revenue PhaseMargin Improvement Report - po-news-eg.net
OrbiMed reports 13.9% Q32 Bio ownership and 45-day lock-up (QTTB) - Stock Titan
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - Yahoo Finance
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio files prospectus for offer and resale of 6.875M shares - scanx.trade
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Q32 Bio: Bempikibart's Progress Keeps Me Bullish (NASDAQ:QTTB) - Seeking Alpha
Boxer Capital Management, LLC Acquires Significant Stake in Q32 Bio Inc - GuruFocus
Why is Q32 Bio stock falling Wednesday? - MSN
Q32 Bio Inc. Announces $300 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement Details and Legal Opinions Included – Minichart - Minichart
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Nigeria
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):